[Phase-II-study with cis-diamminedichloroplatinum (II) in the treatment of advanced malignant lymphomas].
29 patients with advanced malignant lymphoma were included in a phase-II trial conducted by Cancer and Acute Leukemia Group B. The patients received cis-diamminedichloroplatinum (DDP) in a dose of 70 mg/m2 every three weeks. In this still ongoing study, 23 patients are already evaluable. Out of 23 cases partial remission was observed in 6. The main toxicity was profuse vomiting. Myelosuppression and nephrotoxicity were both manageable. Based on these preliminary data, the incorporation of DDP in combination chemotherapy for malignant lymphoma appears to be warranted.
D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin
Phase-II-Studie mit Cis-Diamminedichloroplatinum (II) in der Behandlung fortgeschrittener maligner Lymphome.